Welcome to our dedicated page for Cardiol Therapeu SEC filings (Ticker: CRDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Cardiol Therapeutics Inc. (CRDL) provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Cardiol files reports on Form 6-K under the Securities Exchange Act of 1934, which transmit key documents such as financial statements, management’s discussion and analysis, and material news releases related to its operations as a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease.
Among the filings, investors can find condensed interim consolidated financial statements and accompanying management’s discussion and analysis for specified periods, as referenced in Form 6-K submissions. These documents outline operating results, research and development spending, and other financial information relevant to Cardiol’s clinical programs, including the MAVERIC Program in recurrent pericarditis and the ARCHER trial in acute myocarditis.
Form 6-K filings also incorporate news releases that describe important corporate events. Examples include announcements of private placement financings that support the pivotal Phase III MAVERIC trial and the development of CRD-38, updates on clinical trial milestones such as database lock and topline results from ARCHER, and disclosures about intellectual property developments like the U.S. patent allowance for cannabidiol compositions in heart conditions. Additional exhibits may include reports of exempt distributions and material change reports filed in connection with financings or other significant events.
On Stock Titan, these SEC filings are organized chronologically and can be paired with AI-powered summaries that explain the main points of each document in clear language. Users can quickly scan Form 6-K submissions, understand which exhibits are attached—such as financial statements, certifications of interim filings, or specific news releases—and identify items relevant to Cardiol’s clinical-stage cardiovascular pipeline, regulatory designations, and capital-raising activities.
Cardiol Therapeutics Inc. entered into a bought deal private placement with Canaccord Genuity Corp., which agreed to purchase for resale 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million. The company granted the underwriter an option to buy up to an additional 1,038,462 units at the same price to raise up to a further $1,350,000 in gross proceeds.
Each unit consists of one common share and one-half of one warrant, with each whole warrant exercisable at $1.75 per share for 24 months from issuance. Cardiol plans to use the net proceeds to advance its research and clinical development programs, and for general and administrative expenses, working capital, and other expenses. Closing is targeted on or about January 23, 2026, subject to approvals, including TSX approval and execution of an underwriting agreement.
Cardiol Therapeutics Inc. has closed a previously announced bought-deal private placement of units, raising gross proceeds of $14.85 million. The company issued 11,423,078 units at $1.30 per unit, with each unit consisting of one Class A common share and one-half of a common share purchase warrant. Each whole warrant allows the holder to buy one additional share at an exercise price of $1.75 for 24 months from issuance. Cardiol paid the underwriter, Canaccord Genuity Corp., a cash commission equal to 6% of the gross proceeds. The company plans to use the net proceeds to advance its research and clinical development programs, and to fund general and administrative expenses, working capital, and other corporate needs.
Cardiol Therapeutics Inc. entered into a bought deal private placement, with a sole underwriter agreeing to purchase for resale 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million. The company also granted the underwriter a 10% option for up to 1,038,462 additional units at the same price to cover over-allotments.
Each unit includes one common share and one-half warrant, with each whole warrant exercisable at $1.75 per share for 24 months from issuance. Cardiol plans to use the net proceeds to advance its research and clinical development programs, and for general and administrative expenses, working capital, and other expenses.
The offering is expected to close on or about January 23, 2026, subject to conditions including TSX approval and completion of an underwriting agreement, and will be conducted under Canadian prospectus exemptions, including the Listed Issuer Financing Exemption.
Cardiol Therapeutics reports that its pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis has surpassed 50% patient enrollment, marking a key execution and risk‑reduction milestone for its lead registrational program. More than 15 leading cardiovascular centers in the United States are actively enrolling patients, with additional top-tier sites in Europe and Canada being activated, and the company expects full enrollment to be completed in Q2 2026.
MAVERIC is designed to enroll approximately 110 patients across about 25 centers in North America and Europe, with a primary endpoint of freedom from a new recurrent pericarditis episode after six months of double-blind treatment. The trial builds on positive Phase II MAvERIC-Pilot data showing rapid and sustained reductions in pain, inflammation, and recurrence rates, and on Phase II ARCHER data in myocarditis. Cardiol also highlights Orphan Drug Designation for CardiolRx™ in pericarditis and ongoing development of CRD-38 for inflammatory heart disease, including heart failure.
Cardiol Therapeutics (CRDL) furnished a Form 6-K that includes a news release stating it received a U.S. patent allowance broadly protecting its heart drugs to late 2040. The exhibit is a news release dated November 13, 2025.
The company indicates it files annual reports under cover of Form 40-F as a foreign private issuer.
Cardiol Therapeutics Inc. filed a Form F-10 base shelf registration to offer up to US $150,000,000 of securities under the MJDS. The shelf covers Common Shares, Debt Securities, Warrants, Subscription Receipts, and Units, to be sold from time to time during the 25-month period the prospectus remains effective, with specific terms to be set in prospectus supplements.
Amendment No. 1 adds that one or more selling securityholders may conduct secondary offerings by prospectus supplement, and the aggregate amount available for the company’s sales will be reduced by the aggregate amount of such secondary offerings. Cardiol’s Common Shares trade on the TSX and Nasdaq under “CRDL”.
Cardiol Therapeutics Inc. filed a Form 6-K as a foreign private issuer that reports under Form 40-F. The filing mainly furnishes a news release dated November 5, 2025, announcing that results from its Phase II ARCHER clinical trial will be presented at the European Society of Cardiology’s Scientific Meeting on Myocardial & Pericardial Diseases.